News

Organoid Cryopreservation Handbook

AMSBIO has published an informative handbook for scientists who need to preserve or archive organoids in a research lab.


The handbook brings together published paper citations, quotes and data from leading international research groups who are using the CELLBANKER® range of products to cryopreserve their organoids simply and safely. In addition, the handbook includes best practice protocols plus information making it easier to understand the process of freezing organoids and to choose the optimum cryopreservation media for your application.

Read more

ARECOR TO COMMENCE SECOND CLINICAL TRIAL WITH AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR TYPE 2 DIABETES

Arecor Therapeutics plc

(“Arecor” or the “Group”)


ARECOR TO COMMENCE SECOND CLINICAL TRIAL WITH AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR TYPE 2 DIABETES


Clinical Trial Application approved


EU Phase I clinical trial expected to commence in December 2022

Read more

ARECOR GRANTED KEY PATENT IN JAPAN AND SOUTH KOREA TO PROTECT PROPRIETARY INSULIN PRODUCTS AT247 AND AT278

The granted patents further strengthen the Group’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio


Cambridge, UK, 22 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the Japan Patent Office has granted a patent (JP7145849) protecting novel formulations of the Group’s proprietary insulin products, AT247 and AT278. The same patent has also been granted in South Korea.

Read more

First Dedicated R&D Space Comes to Market at Peterborough Research & Innovation Centre

Newly built Research & Development (R&D) space is available at the Peterborough Research & Innovation Centre on Bishops Road, PE1 5BW.


Read more

One Nucleus Employer of Choice Collaboration with the Future of Work Institute

In May 2022, we were honored to announce our collaboration with the Future of Work Institute (FOWI) to enhance our Employer of Choice webinar series to provide our members with real world insights, guidance, and best practices on becoming employers of choice to attract and develop their best team.


Fast forward five months and we have learnt how to; become a destination workplace, support our employees and colleagues through wellbeing strategies, overcome the challenges around hybrid working and finally, to become a great storyteller.

Read more

Office spaces for rent in Cambridge

Discounted offer will be specified.


Read more

Domainex expands Executive and Management Teams to support ongoing growth

Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has made a number of strategic internal promotions to strengthen its Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company.

Read more

Babraham Research Campus Ltd appoints Kathryn Chapman as Director of Science & Entrepreneurship





Cambridge, UK, 21st November 2022:  Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to announce the appointment of Dr Kathryn Chapman to the newly created role of Director, Science & Entrepreneurship.

Read more

ARECOR ANNOUNCES EXCLUSIVE SPECIALTY HOSPITAL FORMULATION COLLABORATION

Cambridge, UK, 10 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.

Read more

Boyds bolsters regulatory affairs team with key appointment

Leading global drug development consultancy Boyds has appointed experienced regulatory affairs professional and cell and gene therapy expert Dr Patrick Ginty.


With 17 years’ R&D and regulatory affairs experience in regenerative medicine and cell and gene therapy products, Patrick joins Boyds as Senior Director of Regulatory Affairs.

Read more

Pages